The new insulin production facility is at Sanofi’s existing site in Frankfurt, where it makes insulin brand Lantus, the company said on Thursday.
Today’s serving of alphabet noodle soup to the biopharma industry – IRA, JCA, AAV, VC, and PM to list just five – may seem unpalatable, but the bigger picture is enticing. To focus disproportionately on the challenges is an understandable, tactical response, but we feel that the industry is on the cusp of a new era of growth and transformation, and that this should be celebrated.
Sangamo and Pfizer’s hemophilia A gene therapy candidate scored a Phase III victory last week. However, with the genomic medicine company soon to run out of cash, Sangamo’s short-term prospects look bleak but not unsalvageable, analysts say.
Today the British drugmaker GSK cut its forecast for 2024 vaccine sales after quarterly revenue from its blockbuster shingles and respiratory syncytial virus (RSV) jabs missed expectations, sending its shares lower.
The BIOSECURE Act’s prohibition on doing business with China-based companies may have implications for biotech and biopharma markets on both sides of the Pacific.
The company sees its branded medicine trio — Austedo for treating the Huntington’s disease, Ajovy for migraine and recently launched Uzedy for schizophrenia — as growth drivers.